| Literature DB >> 26160868 |
Nicole Sonneveld1, Sanja Stanojevic2, Reshma Amin3, Paul Aurora4, Jane Davies5, J Stuart Elborn6, Alex Horsley7, Philipp Latzin8, Katherine O'Neill6, Paul Robinson9, Emma Scrase4, Hiran Selvadurai9, Padmaja Subbarao10, Liam Welsh11, Sophie Yammine8, Felix Ratjen12.
Abstract
Pulmonary exacerbations are important clinical events for cystic fibrosis (CF) patients. Studies assessing the ability of the lung clearance index (LCI) to detect treatment response for pulmonary exacerbations have yielded heterogeneous results. Here, we conduct a retrospective analysis of pooled LCI data to assess treatment with intravenous antibiotics for pulmonary exacerbations and to understand factors explaining the heterogeneous response.A systematic literature search was performed to identify prospective observational studies. Factors predicting the relative change in LCI and spirometry were evaluated while adjusting for within-study clustering.Six previously reported studies and one unpublished study, which included 176 pulmonary exacerbations in both paediatric and adult patients, were included. Overall, LCI significantly decreased by 0.40 units (95% CI -0.60- -0.19, p=0.004) or 2.5% following treatment. The relative change in LCI was significantly correlated with the relative change in forced expiratory volume in 1 s (FEV1), but results were discordant in 42.5% of subjects (80 out of 188). Higher (worse) baseline LCI was associated with a greater improvement in LCI (slope: -0.9%, 95% CI -1.0- -0.4%).LCI response to therapy for pulmonary exacerbations is heterogeneous in CF patients; the overall effect size is small and results are often discordant with FEV1.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26160868 DOI: 10.1183/09031936.00211914
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671